Technology, Media & Healthcare

How to Underwrite a Healthcare or Life Sciences Company

Underwrite a healthcare or life sciences company by tracing every revenue dollar to who pays for it and under what rules, then testing regulatory compliance and dependence on key clinicians or customers. Key metrics are payer mix and reimbursement rate trends, revenue cycle quality such as days in AR and denial rates, and customer or provider concentration.

What makes healthcare / life sciences underwriting different

Healthcare and life sciences span providers paid by insurers and government programs, outsourced services sold to pharma and biotech, and product companies. What makes the sector distinct is that a third party, often Medicare, Medicaid or a commercial insurer, sets or negotiates price, and regulators decide who may provide the service and how it is billed. Value comes from demographic demand, licenses and certifications that limit competition, and long-term relationships with health systems or drug developers. Risk comes from reimbursement cuts, billing compliance failures, False Claims Act exposure, clinician shortages and, for life sciences services, the funding cycle of biotech customers.

Lenders focus on the predictability of collections. They review payer mix, historical rate changes, revenue cycle performance and compliance history, and they often require healthcare regulatory diligence before funding. Collateral is mainly receivables, valued net of expected denials and contractual adjustments. Equity investors underwrite growth from demographics, consolidation and new service lines, and they model value creation from payer contracting and operating improvements. They will pay premiums for platforms with favorable commercial payer mix, scalable infrastructure and regulatory track records that allow rapid acquisitions.

Key metrics

Payer mix

Commercial, Medicare, Medicaid and self-pay pay very different rates and carry different policy risk.

Investors typically value a higher commercial payer share, while recognizing it can carry renegotiation risk.

Days in accounts receivable

Shows how efficiently claims are billed and collected, and long AR can hide uncollectible balances.

Denial rate and net collection rate

Indicate billing accuracy and the share of expected reimbursement actually collected.

Reimbursement rate trends

Fee schedule changes can reduce revenue for the same volume of services.

Provider or customer concentration

A few physicians, health systems or biopharma clients can drive a large share of revenue.

Labor cost as a percent of revenue

Clinical staff shortages and wage inflation drive margins in most healthcare services.

How to underwrite it, step by step

Map revenue by service line, payer and site, and reconcile billed charges to cash collections.
Review payer contracts, fee schedules and pending rate changes.
Conduct healthcare regulatory diligence covering licensure, billing, coding, Stark, Anti-Kickback and HIPAA.
Analyze revenue cycle metrics including AR aging, denials and bad debt.
Assess clinician employment agreements, compensation models, non-competes and turnover.
For life sciences services, analyze customer funding sources, backlog and contract cancellation history.
Normalize EBITDA for provider compensation changes, out-of-period collections and one-time settlements.
Stress test for reimbursement cuts, payer contract loss and clinician departures.

Due diligence checklist

Revenue and collections by payer, service line and location
Payer contracts and fee schedules
AR aging, denial and bad debt reports
Coding and billing compliance audits
Licenses, accreditations and certifications
Provider employment and compensation agreements
Regulatory correspondence, audits and investigations
HIPAA policies and breach history
Malpractice insurance and claims history
Customer contracts and backlog for life sciences services

Key risks and mitigants

Reimbursement cut

Model revenue at lower rates, review payer mix trends and keep leverage moderate.

Billing or coding compliance failure

Commission coding audits, review compliance programs and require specific indemnities for pre-closing liabilities.

Clinician turnover

Review compensation, contracts and retention, and size debt assuming some departures.

Customer funding cycles in life sciences services

Analyze customer mix by funding stage and stress backlog cancellations.

Regulatory change affecting licensure or ownership

Obtain legal analysis of state rules and structure ownership to comply.

Typical financing and deal structure

Healthcare services companies are typically financed with senior term loans or unitranche facilities sized on EBITDA, plus revolvers that may be secured by receivables. Sponsor-backed platforms use delayed draw term loans for acquisitions. Smaller practices use SBA 7(a) loans or bank loans with seller financing. In states that restrict corporate ownership of medical practices, deals use management services organizations with contractual relationships to professional entities, which affects collateral and covenants. Life sciences services companies often use cash flow loans sized on contracted backlog. Purchase agreements include healthcare regulatory representations and indemnities, and R&W insurance typically excludes known billing issues.

Red flags

An open government investigation or qui tam complaint
Billing patterns that differ sharply from peers without clinical justification
Major payer contract expiring with rate cuts proposed
Revenue dependent on a few physicians with no non-competes
Life sciences customers concentrated in early-stage biotechs with limited funding

Frequently asked questions

What is payer mix and why does it matter?

Payer mix is the share of revenue from commercial insurance, Medicare, Medicaid and self-pay patients. Each pays different rates and carries different risks. Commercial payers usually pay more but can renegotiate. Government programs set rates by regulation and can cut them. Underwriters analyze payer mix to forecast revenue and policy risk.

What does healthcare regulatory due diligence cover?

It reviews licensure, billing and coding practices, compliance with Stark and Anti-Kickback laws, HIPAA, ownership restrictions and any government audits or investigations. Findings can affect valuation, deal structure and indemnities. Lenders and buyers often require a specialized healthcare counsel review before closing because these liabilities can be large and survive the sale.

How do lenders evaluate healthcare receivables?

Lenders look at AR aging, payer mix, denial rates and historical collections to estimate collectible value. Government and commercial receivables are typically eligible, while self-pay and older balances may be excluded. Advance rates reflect expected collections after contractual adjustments, and lenders may require lockbox arrangements for government payments.

How are healthcare services companies valued?

They are typically valued on EBITDA multiples that depend on scale, growth, payer mix, margin and regulatory risk. Platforms with strong commercial payer relationships, scalable infrastructure and acquisition track records often command higher multiples. Underwriters adjust EBITDA for provider compensation and out-of-period collections before applying a multiple.

Underwrite a healthcare / life sciences deal in minutes

Drop a deck or data room. Underridge returns a verdict, investment memo, term sheet and a live model, with every headline figure traced to a page, a formula or a labeled assumption. Ten underwrites free.

Try Underridge free

Educational content, not investment, credit, legal or tax advice. Benchmarks are common practitioner rules of thumb and vary by lender, market and cycle.